News
The “Top 10” list of best-selling gene therapies published by Genetic Engineering & Biotechnology News (GEN) in their May 2026 issue features three products based upon license agreements for technologies originating from the NIH Intramural Research Program. Featured and ranked on the GEN list are
Meet with a NIH Technology Transfer expert at The Maryland Tech Council’s Bio Innovation Conference on September 4th. This event brings together the region’s top life sciences professionals with global industry leaders, venture capitalists, and innovative startups. NIH Technology Transfer is always
Join the Federal Laboratory Consortium for an informational webinar on how to license technologies from the NIH. The U.S. government invests heavily into healthcare research and development through the NIH but needs commercial partners in order to develop these products and bring them to market
NIH is seeking a licensee or collaborator for Nipamovir, an affordable oral treatment for HIV infection with a high barrier to resistance. Nipamovir is a low molecular weight mercaptobenzamide derivative that is simple to produce and can be used to lower or eliminate the infectivity of HIV. It